Vanda Pharmaceuticals Net Worth
Vanda Pharmaceuticals Net Worth Breakdown | VNDA |
Vanda Pharmaceuticals Net Worth Analysis
Vanda Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vanda Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vanda Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vanda Pharmaceuticals' net worth analysis. One common approach is to calculate Vanda Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vanda Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vanda Pharmaceuticals' net worth. This approach calculates the present value of Vanda Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vanda Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vanda Pharmaceuticals' net worth. This involves comparing Vanda Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vanda Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Vanda Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vanda Pharmaceuticals' net worth research are outlined below:
| Vanda Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Vanda Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 77.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Stephen Ray Mitchell Sells 5,000 Shares of Vanda Pharmaceuticals Inc. Stock |
Vanda Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vanda Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vanda Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Vanda Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vanda Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vanda Pharmaceuticals backward and forwards among themselves. Vanda Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vanda Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prudential Financial Inc | 2024-09-30 | 776.8 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 725.4 K | Federated Hermes Inc | 2024-09-30 | 716.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 596.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 559.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 526.8 K | Northern Trust Corp | 2024-09-30 | 501.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 419.5 K | Krensavage Asset Management, Llc | 2024-09-30 | 414.7 K | Blackrock Inc | 2024-06-30 | 8.1 M | Renaissance Technologies Corp | 2024-09-30 | 4 M |
Follow Vanda Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 314.86 M.Market Cap |
|
Project Vanda Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.02) | (0.03) |
When accessing Vanda Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vanda Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vanda Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Vanda Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vanda Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Vanda Pharmaceuticals' management manipulating its earnings.
Evaluate Vanda Pharmaceuticals' management efficiency
Vanda Pharmaceuticals has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0302) %, meaning that it created substantial loss on money invested by shareholders. Vanda Pharmaceuticals' management efficiency ratios could be used to measure how well Vanda Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Vanda Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0, whereas Return On Capital Employed is forecasted to decline to (0.03). At present, Vanda Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 226.3 M, whereas Other Current Assets are forecasted to decline to about 7.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.50 | 9.97 | |
| Tangible Book Value Per Share | 7.38 | 7.75 | |
| Enterprise Value Over EBITDA | (10.58) | (11.11) | |
| Price Book Value Ratio | 0.44 | 0.42 | |
| Enterprise Value Multiple | (10.58) | (11.11) | |
| Price Fair Value | 0.44 | 0.42 | |
| Enterprise Value | 115.7 M | 109.9 M |
Management at Vanda Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 0.5857 | Revenue 190.9 M | Quarterly Revenue Growth 0.228 | Revenue Per Share 3.293 | Return On Equity (0.03) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vanda Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vanda Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vanda Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vanda Pharmaceuticals Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of May 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Vanda Pharmaceuticals Earnings per Share Projection vs Actual
Vanda Pharmaceuticals Corporate Management
| Scott Howell | Chief Officer | Profile | |
| Mihael MD | President, Founder | Profile | |
| Kevin Moran | CFO VP | Profile | |
| Elizabeth Every | Head Affairs | Profile | |
| Joakim Wijkstrom | Chief Marketing Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share (0.19) | Revenue Per Share 3.293 | Quarterly Revenue Growth 0.228 | Return On Assets (0.04) |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.